Differential modulation of cytokine production in major depressive disorder by cortisol and dexamethasone

European Neuropsychopharmacology

Volumn 18, Issue 12, 2008, Pages 860-870

  Heiser, P ^a,b   Lanquillon, S ^a   Krieg, J C ^a   Vedder, H ^a,c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Department of General Psychiatry and Psychotherapy   (Germany)

Author keywords

Cortisol; Dexamethasone; Immune response; Interleukin 6; Major depressive disorder; Tumor necrosis factor

Indexed keywords

DEXAMETHASONE; HYDROCORTISONE; INTERLEUKIN 6; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; IMMUNE RESPONSE; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; BLOOD CELLS; CASE-CONTROL STUDIES; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROCORTISONE; INTERLEUKIN-6; MALE; MIDDLE AGED; STATISTICS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 53649104132     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.07.003     Document Type: Article

References (47)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, IV (DSM IV) (1994), American Psychiatric Press, Washington, D.C.
2. Anisman H., and Merali Z. Cytokines, stress and depressive illness: brain-immune interactions (review). Ann. Med. 35 (2003) 2-11
3. Bauer M.E., Papadopoulos A., Poon L., Perks P., Lightman S.L., Checkley S., and Shanks N. Dexamethasone-induced effects on lymphocyte distribution and expression of adhesion molecules in treatment-resistant depression. Psychiatry Res. 113 (2002) 1-15
4. Bauer M.E., Papadopoulos A., Poon L., Perks P., Lightman S.L., Checkley S., and Shanks N. Altered glucocorticoid immunoregulation in treatment resistant depression. Psychoneuroendocrinology 28 (2003) 49-65
5. Baumgartner R.A., Deramo V.A., and Beaven M.A. Constitutive and inducible mechanisms for synthesis and release of cytokines in immune cell lines. J. Immunol. 157 (1996) 4087-4093
6. Cupps T.R., and Fauci A.S. Corticosteroid-mediated immunoregulation in man. Immunol. Rev. 65 (1982) 133-155
7. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann. N. Y. Acad. Sci. 933 (2001) 222-234
8. De Groote D., Gevaert Y., Lopez M., Gathy R., Fauchet F., Dehart I., Jadoul M., Radoux D., and Franchimont P. Novel method for the measurement of cytokine production by a one-stage procedure. J. Immunol. Methods 163 (1993) 259-267
9. De Kloet E.R., Oitzl M.S., and Schobitz B. Cytokines and the brain corticosteroid receptor balance: relevance to pathophysiology of neuroendocrine-immune communication. Psychoneuroendocrinology 19 (1994) 121-134
10. DeRijk R., and Sternberg E.M. Corticosteroid resistance and disease. Ann. Med. 29 (1997) 79-82
11. Dhabhar F.S., and McEwen B.S. Enhancing versus suppressive effects of stress hormones on skin immune function. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 1059-1064
12. Fantuzzi G., Demitri M.T., and Ghezzi P. Differential effect of glucocorticoids on tumour necrosis factor production in mice: up-regulation by early pretreatment with dexamethasone. Clin. Exp. Immunol. 96 (1994) 166-169
13. Frommberger U.H., Bauer J., Haselbauer P., Raulin A., Riemann D., and Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci. 247 (1997) 228-233
14. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
15. Herbert T.B., and Cohen S. Depression and immunity: a meta-analytic review. Psychol. Bull. 113 (1993) 472-486
16. Holsboer F. The corticosteroid receptor hypothesis of depression (review). Neuropsychopharmacology 23 (2000) 477-501
17. 1 receptor antagonists for the treatment of depression and anxiety. Exp. Clin. Psychopharmacol. 15 (2007) 519-528
18. Kok F.W., Heijnen C.J., Bruijn J.A., Westenberg H.G.M., and van Ree J.M. Immunoglobulin production in vitro in major depression: a pilot study on the modulating action of endogenous cortisol. Biol. Psychiatry 38 (1995) 217-226
19. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., and Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22 (2000) 370-379
20. Leonard B. Stress, depression and the activation of the immune system (review). World J. Biol. Psychiatry 1 (2000) 17-25
21. Licinio J., and Wong M.L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry 4 (1999) 317-327
22. Lim-Tio S.S., Keightley M.C., and Fuller P.J. Determinants of specificity of transactivation by the mineralocorticoid or glucocorticoid receptor. Endocrinology 138 (1997) 2537-2543
23. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 19 (1995) 11-38
24. Maes M., Scharpe S., Meltzer H.Y., Bosmans E., Suy E., Calabrese J., and Cosyns P. Relationships between interleukin-6 activity, acute phase proteins and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res. 49 (1993) 11-27
25. Maes M., Bosmans E., De Jongh R., Kenis G., Vandoolaeghe E., and Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9 (1997) 853-858
26. Mikova O., Yakimova R., Bosmans E., Kenis G., and Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur. Neuropsychopharmacol. 11 (2001) 203-208
27. Miller G.E., Rohleder N., Stetler C., and Kirschbaum C. Clinical depression and regulation of the inflammatory response during acute stress. Psychosom. Med. 67 (2005) 679-687
28. Modell S., Yassouridis A., Huber J., and Holsboer F. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 65 (1997) 216-222
29. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-389
30. Moynagh P.N. Toll-like receptor signaling pathways as key targets for mediating the anti-inflammatory and immunosuppressive effects of glucocorticoids. J. Endocrinol. 179 (2003) 139-144
31. Pariante C.M., and Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49 (2001) 391-404
32. Raison C.L., and Miller A.H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders (review). Am. J. Psychiatry 160 (2003) 1554-1565
33. Rakasz E., Gal A., Biró J., Balas G., and Falus A. Modulation of glucocorticosteroid binding in human lymphoid, monocytoid and hepatoma cell lines by inflammatory cytokins Interleukin (IL)-1β, IL-6 and Tumour Necrosis Factor (TNF)-α. Scand. J. Immunol. 37 (1993) 684-689
34. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., and Pollmächer T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 58 (2001) 445-452
35. Renz H., Henke A., Hofmann P., Wolff L.J., Schmidt A., Rüschoff J., and Gemsa D. Sensitization of rat alveolar macrophages to enhanced TNF-α release by in vivo treatment with dexamethasone. Cell. Immunol. 144 (1992) 249-257
36. Ribeiro S.C., Tandon R., Grunhaus L., and Greden J.F. The DST as a predictor of outcome in depression: a meta-analysis. Am. J. Psychiatry 150 (1993) 1618-1629
37. Sapolsky R.M., Romero L.M., and Munck A.U. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21 (2000) 55-89
38. Schiepers O.J., Wichers M.C., and Maes M. Cytokines and major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 201-217
39. Schuld A., Schmid D.A., Haack M., Holsboer F., Friess E., and Pollmächer T. Hypothalamo-pituitary-adrenal function in patients with depressive disorders is correlated with baseline cytokine levels, but not with cytokine responses to hydrocortisone. J. Psychiatr. Res. 37 (2003) 463-470
40. Sluzewska A., Rybakowski J.K., Laciak M., Mackiewicz A., and Sobieska M. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. N.Y. Acad. Sci. 762 (1995) 474-476
41. Tichomirowa M.A., Keck M.E., Schneider H.J., Paez-Pereda M., Renner U., Holsboer F., and Stalla G.K. Endocrine disturbances in depression. J. Endocrinol. Investig. 28 (2005) 89-99
42. Vedder H., Schreiber W., Schuld A., Kainz M., Lauer C.J., Krieg J.C., Holsboer F., and Pollmächer T. Immune-endocrine host response to endotoxin in major depression. J. Psychiatr. Res. 41 (2007) 280-289
43. Weizman R., Laor N., Podliszewski E., Notti I., Djaldetti M., and Bessler H. Cytokine production in major depressed patients before and after clomipramine treatment. Biol. Psychiatry 35 (1994) 42-47
44. Wittchen H.U., Zaudig M., and Fydrich T. Strukturiertes Klinisches Interview für DSM-IV (SKID-I und SKID-II) (1995), Hogrefe Verlag, Göttingen
45. Wodarz N., Rupprecht R., Kornhuber J., Schmitz B., Wild K., Braner H.U., and Riederer P. Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression. J. Affect. Disord. 22 (1991) 241-248
46. Yu S., Holsboer F., and Almeida O.F. Neuronal actions of glucocorticoids: focus on depression. J. Steroid Biochem. Mol. Biol. 108 (2008) 300-309
47. Zobel A.W., Nickel T., Sonntag A., Uhr M., Holsboer F., and Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study. J. Psychiatr. Res. 35 (2001) 83-94